Skip to search formSkip to main contentSkip to account menu

PV701

Known as: PV 701, PV-701 
An attenuated, replication-competent, oncolytic strain of Newcastle disease virus. PV701 selectively lyses tumor cells. The selectivity of this agent… 
National Institutes of Health

Related topics

Related topics

2 relations
Neoplastic CellPositive Regulation of Cytolytic Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Oncolytic virus therapy--foreword.
We are very pleased and proud to be able to publish this special issue of Current Cancer Drug Targets devoted to oncolytic virus… 
2007
2007
Gene therapy for cancer
Table of Contents CANCER GENE THERAPY Introduction - Kelly K. Hunt, M.D. and Stephan A. Vorburger, M.D., M.C.R. Vectors 1… 
2006
2006
PV 701: two-step desensitisation improves tolerability
  • 2006
  • Corpus ID: 195122328
2005
2005
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
2004
2004
Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study
3037 Background: PV701 is a non-recombinant, replication-competent Newcastle disease virus that targets tumor-specific defects in… 
2004
2004
Genes in the service of therapeutic index: progress for virus-directed enzyme prodrug therapy.
It has been a difficult past half-decade or so for would-be gene therapists. In contrast to the rather heady prospects in the… 
2004
2004
Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study.
3037 Background: PV701 is a non-recombinant, replication-competent Newcastle disease virus that targets tumor-specific defects in… 
2003
2003
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2001
2001
An intravenous phase I trial of PV701, a replication-competent virus, in the treatment of patients with advanced solid cancers
2001
2001
The broad spectrum oncolytic activity of newcastle disease virus, PV701, is a result of a functional defect in the antiviral interferon response of tumor cells
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)